[1]朱丹.回生口服液联合多西紫杉醇同期放化疗治疗食管癌临床研究[J].陕西中医,2018,(10):1372-1374.
 Zhu Dan..Clinical analysis of concurrent chemotherapy and radiotherapy in patients with esophageal cancer treated by combination of Hui Sheng oral liquid and docetaxel[J].,2018,(10):1372-1374.
点击复制

回生口服液联合多西紫杉醇同期放化疗治疗食管癌临床研究
分享到:

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2018年10期
页码:
1372-1374
栏目:
临床研究
出版日期:
2018-12-31

文章信息/Info

Title:
Clinical analysis of concurrent chemotherapy and radiotherapy in patients with esophageal cancer treated by combination of Hui Sheng oral liquid and docetaxel
文章编号:
DOI: 10.3969/j.issn.1000-7369.2018.10.017
作者:
朱丹
湖北省宜昌市第二人民医院药剂科 (宜昌 443000)
Author(s):
Zhu Dan.
Department of Pharmacy, the Second People’s Hospital of Yichang City in Hubei Province (Yichang 443000)
关键词:
食管肿瘤/中西医结合疗法化学疗法@回生口服液@多西紫杉醇
Keywords:
Key words Esophageal neoplasms/integrated Chinese traditional and western medicine therapyChemotherapy adjuvant@Hui Sheng oral liquid@Docetaxel
分类号:
R735.1
文献标志码:
A
摘要:
摘要 目的:探讨回生口服液联合多西紫杉醇同期放化疗治疗食管癌的临床疗效。方法:选取食管癌患者92例,按照随机数字表法,分为对照组与观察组,各46例。对照组采用放疗联合多西紫杉醇静脉化疗治疗,观察组在对照组基础上,加用回生口服液进行治疗,比较两组治疗效果及不良反应发生情况。结果:治疗后,观察组的T细胞亚群(CD3+,CD4+,CD8+,CD4+/CD8+)及NK细胞水平改善情况优于对照组,差异具有统计学意义(P<0.05);观察组(86.96%)和对照组(82.61%)的临床疗效差异无统计学意义(P>0.05);观察组放射性食管炎(4.35%)、放射性肺炎(2.17%)、骨髓抑制不良反应发生率(2.1%)与对照组(6.52%、4.35%、6.52%)比较的差异均无统计学意义(P>0.05)。但2 级及以上血液系统毒性发生率,观察组明显低于对照组(P<0.05)。结论:回生口服液联合多西紫杉醇同期放化疗食管癌的临床疗效显著,可改善患者的免疫功能,降低不良反应发生率,值得在临床上应用。
Abstract:
Abstract Objective: To investigate the clinical efficacy of combination of chemotherapy with retroactive oral liquid and docetaxel in the treatment of esophageal cancer. Methods: 92 cases of esophageal cancer were randomly divided into control group and observation group, 46 cases in each group. The control group was treated with radiotherapy combined with docetaxel intravenous chemotherapy, and the observation group was treated with the rebirth oral liquid on the basis of the control group. The treatment effect and the adverse reaction of the two groups were compared. Results: After treatment, the improvement of T cell subgroup and NK cell level (CD3+,CD4+,CD8+,CD4+/CD8+) in the observation group was better than that of the control group, the difference was statistically significant (P<0.05), the difference of clinical efficacy between the observation group (86.96%) and the control group (82.61%) was not statistically significant (P>0.05), and there was no significant difference between the observation group radiation esophagitis (4.35%), the radioactive pneumonia (2.17%), myelosuppression (2.1%) and the control group 6.52%, 4.35%, 6.52% (P>0.05). However, the difference of the incidence of hematological toxicity in grade 2 and the above grade were significantly lower in the observation group than in the control group (P<0.05). Conclusion: The clinical effect of rebirth oral liquid combined with docetaxel in the concurrent chemotherapy of esophageal cancer is significant. It can improve the immune function of the patients and reduce the incidence of adverse reactions. It is worthy of clinical application.

参考文献/References:


[1] 薛峰,苏进,许新华.回生口服液联合同步放化疗治疗中晚期食管癌效果观察[J].山东医药,2011,51(19):73-74.
[2]李志玖,艾淑颖,周勇,等.回生口服液联合适形放疗治疗食管癌的临床观察[J].实用癌症杂志,2013,28(6):773-774.
[3]陈云萍,张江灵,赵义名.奥沙利铂联合紫杉醇治疗晚期难治性食管癌临床疗效分析[J].现代肿瘤医学,2013,21(8):1789-1791.
[4 ]陈豫民,王波,邓毛,等.回生口服液用于中晚期食管癌同期放化疗患者疗效观察[J].山西医药杂志,2014,43(22):2674-2676.
[5]罗海涛,古伟光,胡建新.三维适形放疗联合多西紫杉醇化疗治疗食管癌的临床观察[J].现代肿瘤医学,2011,19(8):1559-1561.
[6]马代远,谭榜宪,柳弥,等.回生口服液联合单药奈达铂同步放化疗治疗不可切除局部晚期非小细胞肺癌[J].第三军医大学学报,2013,35(2):179-181.
[7]莫如康,刘图强,陈炳光,等.以奈达铂联合多西紫杉醇为基础的同步放化疗治疗不可手术食管癌的临床结果[J].中国医药导报,2012,9(5):71-73.
[8]董华琼,刘发兰,田婕丽,等.回生口服液联合多西紫杉醇同期放化疗治疗60 例食管癌临床分析[J].第三军医大学学报,2012,34(24):2473,2483.
[9]高伟生.回生口服液辅助治疗恶性肿瘤127 例效果观察[J].山东医药,2011,51(51):110-111.
[10]付娟.回生口服液的药理作用和临床应用[J].山东医药,2011,51(11):110-111.
[11]张传建,刘化勇.回生口服液联合放化疗治疗中晚期头颈部恶性肿瘤51例效果观察[J].山东医药,2011,51(51):100-101.
[12]曾金武,张家洪.回生口服液辅助治疗中晚期肺癌56例[J].中国药业,2014,23(8):73.
[13]王道梅,燕平,莫正英,等.回生口服液对非小细胞肺癌化疗患者血象及免疫功能的影响[J].中国中医药信息杂志,2007,14(10):67,78.

更新日期/Last Update: 2019-01-07